LIFSHATZ STEPHEN J
Known title: DirectorCIK: 0001221302
Associated companies
Transaction History
| DT | ▲ Buy | Option Exercise | 4,111 | — | 8/20/2026 | View on chart |
| DT | ▲ Buy | Option Exercise | 3,981 | — | 8/20/2025 | View on chart |
| DT | ▼ Sell | Open Market | 2,500 | $152K | 2/10/2025 | View on chart |
| DT | ▼ Sell | Open Market | 2,500 | $138K | 11/5/2024 | View on chart |
| DT | ▼ Sell | Open Market | 5,000 | $275K | 10/11/2024 | View on chart |
| DT | ▲ Buy | Grant | 3,981 | $0 | 8/23/2024 | View on chart |
| DT | ▲ Buy | Grant | 4,290 | $0 | 8/23/2023 | View on chart |
| DT | ▲ Buy | Grant | 5,190 | $0 | 8/24/2022 | View on chart |
| DT | ▲ Buy | Grant | 3,010 | $0 | 8/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Dynatrace Completes Arize Acquisition, UBS Raises Target to $74
Dynatrace has finished acquiring Arize to expand its AI observability capabilities across the development lifecycle. UBS responded by raising its price target to $74, citing potential growth in the AI sector. The stock is currently trading near its 52-week high, with an RSI of 71.9 suggesting it may be overbought.
Dynatrace Completes Arize Acquisition, UBS Raises Target to $74. Dynatrace has finished acquiring Arize to expand its AI observability capabilities across the development lifecycle. UBS responded by raising its price target to $74, citing potential growth in the AI sector. The stock is currently trading near its 52-week high, with an RSI of 71.9 suggesting it may be overbought.